RxDoctor Payments Data

Shahid Khan, MD

Cardiovascular Disease · Memphis, TNNPI 1417968314

Payments from drug & device makers

$10,950in general payments, 2019–2025

Across 584 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$1K
  • Actelion Pharmaceuticals US, Inc.$871
  • Amarin Pharma, Inc.$815
  • AstraZeneca$572
  • Philips North America LLC$540
  • plus $6K from 37 others

What the payments were for

  • Food & beverage$10,28594%
  • Education$300%
  • Other$6346%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,950 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$548,038
Medicare patients
841
Services billed
6,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban719$974,803
EntrestoSacubitril/Valsartan449$672,295
OpsumitMacitentan30$378,917
AdempasRiociguat26$355,183
FarxigaDapagliflozin Propanediol210$262,412
XareltoRivaroxaban148$179,091
Repatha SureclickEvolocumab178$170,638
JardianceEmpagliflozin107$133,407
Ranolazine ErRanolazine435$68,495
BrilintaTicagrelor50$47,346
Praluent PenAlirocumab44$33,171
EdarbyclorAzilsartan Med/Chlorthalidone54$30,760
Repatha SyringeEvolocumab20$19,766
VascepaIcosapent Ethyl30$18,911
Isosorbide Mononitrate ErIsosorbide Mononitrate1,449$18,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$349$974,803719 claims
NovartisEntresto$1,077$672,295449 claims
Actelion Pharmaceuticals US, Inc.Opsumit$871$378,91730 claims
BayerAdempas$379$355,18326 claims
AstraZenecaFarxiga, Brilinta$572$309,757260 claims
Johnson & JohnsonXarelto$459$179,091148 claims
Boehringer IngelheimJardiance$444$133,407107 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$112$30,76054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →